Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Personalis (NASDAQ:PSNL) from a sell rating to a hold rating in a report issued on Sunday.

A number of other brokerages have also weighed in on PSNL. Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of Personalis in a research report on Wednesday, November 5th. HC Wainwright raised their price target on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Needham & Company LLC upped their price objective on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. BTIG Research increased their target price on Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Finally, Guggenheim boosted their price target on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.57.

Personalis Price Performance

Personalis stock opened at $8.77 on Friday. Personalis has a 1 year low of $2.83 and a 1 year high of $11.40. The firm’s 50 day moving average price is $9.02 and its 200-day moving average price is $6.92. The stock has a market cap of $778.78 million, a P/E ratio of -9.97 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. As a group, equities analysts expect that Personalis will post -1.4 EPS for the current year.

Insider Buying and Selling at Personalis

In other news, CEO Christopher M. Hall sold 29,612 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Aberdeen Group plc grew its stake in shares of Personalis by 472.3% during the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after buying an additional 1,406,895 shares during the last quarter. American Century Companies Inc. boosted its holdings in Personalis by 33.9% during the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after acquiring an additional 17,056 shares during the period. EntryPoint Capital LLC grew its position in Personalis by 76.0% in the 1st quarter. EntryPoint Capital LLC now owns 83,628 shares of the company’s stock valued at $294,000 after acquiring an additional 36,115 shares during the last quarter. Trexquant Investment LP increased its stake in Personalis by 455.0% in the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock worth $432,000 after purchasing an additional 100,804 shares during the period. Finally, Royal Bank of Canada lifted its position in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.